chevron-down Created with Sketch Beta.
September 22, 2023

Study Examines Challenges and Opportunities for Operationalizing Coverage of OTC Birth Control

This summer, the FDA approved Opill, the first daily oral contraceptive for over-the-counter (OTC) sale. On September 14, 2023, the Kaiser Family Foundation published a study in which researchers conducted 35 structured interviews of nearly 80 experts involved in the covering and providing OTC contraception. Informed by these experts’ experiences with OTC medications, COVID test kits, and Narcan, these interviews discussed potential challenges and opportunities for patient access to the new OTC daily oral contraceptive. Interviewees reported that there was interest in the new contraceptive’s potential to increase access to contraceptive options, but concerns about affordability and coverage remain. KFF proposes a number of “key takeaways” focusing  on policy and coverage implementation changes to adjust to the realities of OTC delivery.

The material in all ABA publications is copyrighted and may be reprinted by permission only. Request reprint permission here.